drugset / Trial / NCT03815461
Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
This single-arm, Phase II clinical trial is to evaluate the efficacy and safety of nab-paclitaxel plus S-1 in locally advanced pancreatic cancer who were borderline resectable or unresectable .
Timeline
- Start
- 2019-02-01
- Primary completion
- 2023-06-01
- Completion
- 2023-10-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nab-paclitaxel | Small molecule | 125 mg/m2 | Intravenous |
| Subject | S-1 | Small molecule | 80 mg | — |
| Subject | S-1 | Small molecule | 100 mg | — |
| Subject | S-1 | Small molecule | 120 mg | — |